Pharmaceuticals & Biopharmaceuticals

Bridgewater, N.J. – October 30, 2026 -- RVL Pharmaceuticals reported double-digit year-over-year revenue growth in the third quarter, driven by rising consumer demand for its prescription eye drop Upneeq, a national celebrity campaign and a widened product line.

Upneeq anchors RVL's vertically integrated platform

Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%) treats acquired blepharoptosis, or low-lying eyelids. It is the core asset of RVL's omnichannel platform, which combines consumer demand generation, healthcare provider engagement, telemedicine, pharmacy fulfillment and data-driven insights. RVL puts the total addressable market for Upneeq at an estimated $2.5 billion.

BOSTON – October 30, 2026 -- Medicilon presented Revolution Medicines, Inc. with its "Excellence in Client Partnership Award" after more than three years of joint work on pan-KRAS drug discovery, following the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib in metastatic pancreatic cancer.

Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, and Senior Scientist Dr. Kristof Pota received the award during a visit to Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, and Dr. Jian Wang, Vice President, hosted the delegation.

TAIPEI – October 30, 2026 -- HanchorBio (TWSE: 7827) has received Taiwan Food and Drug Administration approval for the Investigational New Drug application for HCB303, its trispecific TIGIT-Fc ligand-trap fusion protein, following U.S. FDA clearance. The approval was granted to its wholly owned subsidiary, FBD Biologics Limited, and gives the asset regulatory authorization for clinical investigation in two jurisdictions.

TFDA used a 15-day accelerated pathway for multinational trials

HCB303 cleared through Taiwan's accelerated review route for multinational, multicenter clinical trials, which provides a 15-day review for eligible applications. TFDA has also simplified submission requirements for qualifying first-in-human studies. Under applicable conditions, sponsors no longer need to submit institutional review board approval letters from foreign participating hospitals.

North Brunswick, N.J. – October 30, 2026 -- All five antibody-deficient mice treated with Lactiga's LCTG-001 survived influenza infection, compared with two of five in the control group, according to a peer-reviewed preclinical study conducted by McMaster University scientists in collaboration with Lactiga US, Inc.

The research was published in Science Advances on October 14, 2026. LCTG-001 is a nasal antibody treatment made from secretory immunoglobulin A (sIgA) purified from donated human breast milk. Lactiga is developing it for patients with common variable immunodeficiency (CVID) who keep getting respiratory infections despite existing therapies.

Warren – October 30, 2026 -- PTC Therapeutics (NASDAQ: PTCT) reported third-quarter 2026 total revenue of $358 million and raised its full-year product revenue guidance to $960 million to $990 million, up from $850 million to $950 million. Total revenue guidance for 2026 now stands at $1.29 billion to $1.32 billion.

Product revenue more than doubles on Sephience launch

Net product revenue across the commercial portfolio reached $275.9 million, against $131.0 million in the third quarter of 2025. Net product and royalty revenue combined totaled $357.6 million, compared with $201.7 million a year earlier.

Sephience (sepiapterin) generated $181.9 million, up 20% from the second quarter. US sales were $145 million and ex-US sales $37 million. More than 2,000 patients were on therapy worldwide as of September 30. CEO Matthew Klein said the launch has been a success by all measures and that PTC is on track to reach cash flow breakeven this year.

STOCKHOLM – October 30, 2026 -- The Nomination Committee of Swedish Orphan Biovitrum AB (Sobi) proposes Börje Ekholm, who recently stepped down as CEO of Ericsson, as new Board member and Chair at the 2027 Annual General Meeting (AGM). He would succeed David Meek, who has told the committee he will not stand for re-election.

Meek stays on as Chair until May 2027

Meek has served on Sobi's Board and as Chair since December 2024 and will remain Chair for the rest of his term, which runs to May 2027. The committee credits his tenure with strong growth and shareholder return, wider patient access through new launches and indication extensions, and a stronger clinical development pipeline.

SHANGHAI – October 30, 2026 -- Phrontline Biopharma reported partial responses in six of eight response-evaluable urothelial carcinoma patients (75%) treated with its bispecific antibody-drug conjugate (ADC) TJ101, and has dosed the first patient in a Phase Ib trial.

TJ101 produces responses in patients previously treated with EV and pembrolizumab

The data were presented at the ESMO Congress 2026 in Madrid on October 23, 2026. Responders included patients previously treated with enfortumab vedotin (EV) and pembrolizumab. The results are preliminary and come from a small patient group. The company itself cautions that such findings may not predict outcomes in later studies.

Boston – October 30, 2026 -- Bambusa Therapeutics (Nasdaq: BBTX) priced its upsized initial public offering at $16.00 per share, raising expected gross proceeds of $168,888,880 from the sale of 10,555,555 common shares.

Underwriters hold a 30-day option on 1,583,333 additional shares

The clinical-stage biopharmaceutical company granted its underwriters the option to buy up to 1,583,333 more shares at the IPO price, less underwriting discounts and commissions. Bambusa is the sole seller; all shares in the offering come from the company. The gross figure is before underwriting discounts, commissions and other offering expenses.

Trading on Nasdaq Global Select Market begins October 30

Shares are expected to start trading on October 30, 2026, under the ticker BBTX. The offering is expected to close on November 2, 2026, subject to customary closing conditions.

Rochester, N.Y. -- AeroSafe Global will host a virtual Sustainability Symposium on November 10, 2026, to present closed-loop reuse systems for cold-chain packaging that it says can cut landfill waste by up to 95%.

Single academic medical center handles nearly 300,000 pounds of gel packs a year

The event targets single-use cold-chain packaging as a contributor to the healthcare waste stream. According to AeroSafe, one academic medical center can process nearly 300,000 pounds of single-use gel packs annually. The session will test whether circular delivery models and reverse logistics can remove that waste at source while keeping thermal integrity intact for critical therapies.

Stockholm – October 30, 2026 -- Eisai will present five years of Clarity AD data on lecanemab (Leqembi) at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026, according to its partner BioArctic AB (Nasdaq Stockholm: BIOA B). The dataset spans the core and long-term extension phases and is one of the longest follow-up sets reported to date for an approved anti-amyloid Alzheimer's therapy.

LEADER study tests lecanemab in US clinical practice three years after approval

A symposium on Wednesday, November 18, 11:00-11:40 AM ET, will cover the retrospective, multicenter LEADER study. The study draws on real-world data from different types of US treatment centers, three years after FDA approval.

Three analyses are scheduled: utilization and outcomes from initiation through maintenance therapy, sex-based outcomes, and at-home subcutaneous administration.